Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Brittany Demers"'
Autor:
Ralph V. Boccia, Kimberly Bogard, Stephen J. Noga, Robert M. Rifkin, Habte A. Yimer, Sudhir Manda, Haresh S. Jhangiani, Roger M. Lyons, Brittany Demers, Renda H. Ferrari, Suman Kambhampati, Dasha Cherepanov, Ruemu Ejedafeta Birhiray, Veena Charu, Christopher A. Yasenchak, Saulius Girnius, Jack Aiello, Presley Whidden, Vickie Lu
Publikováno v:
Clinical Lymphoma, Myeloma & Leukemia
Background The ongoing US MM-6 study is investigating in-class transition (iCT) from parenteral bortezomib-based induction to all-oral ixazomib-lenalidomide-dexamethasone (ixazomib-Rd) with the aim of increasing proteasome inhibitor (PI)-based treatm
Autor:
Saad Z. Usmani, Lenka Capkova, Brittany Demers, Jiri Silar, Matyáš Kuhn, Jiri Minarik, Jeffrey A. Zonder, Evangelos Terpos, Andrew Spencer, Caitlin Costello, Dawn Marie Stull, Jan Straub, Ludek Pour, Jorge Vela-Ojeda, Jin Lu, Noemi Puig, Jennifer Elliott, Tomas Skacel, Michael A. Thompson, Frits van Rhee, Mario Boccadoro, Xavier Leleu, Vania Hungria, Robert M. Rifkin, Hans C. Lee, Kaili Ren, Kenny Galvez, Faith E. Davies, Ajai Chari, Alexandra Jungova, Rafat Abonour, Jesus G. Berdeja, Lucie Brožová, Roman Hájek, Magda Bařinová, Vladimir Maisnar, Gordon Cook, Katja Weisel
Publikováno v:
Blood. 134:1845-1845
Background Ixazomib, the first oral proteasome inhibitor, has been approved for >3 years in >70 countries, for the treatment of RRMM pts who have received ≥1 prior therapy, on the basis of the TOURMALINE-MM1 study, which reported an overall respons
Autor:
Andrew Spencer, Saad Z. Usmani, Vania Hungria, Tomas Skacel, Kaili Ren, Alfonso Aguarón, Hans C. Lee, Hartmut Goldschmidt, Jim Omel, Caitlin Costello, Brittany Demers, Xavier Leleu, Jeffrey A. Zonder, Noemi Puig, Mario Boccadoro, Gordon Cook, Faith E. Davies, Shawn Yu, Michael A. Thompson, Jorge Vela-Ojeda, Robert M. Rifkin, Jesus G. Berdeja, Rafat Abonour, Ajai Chari, Roman Hájek, Evangelos Terpos, Dawn Marie Stull
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 18:S247-S248
Autor:
Ralph V. Boccia, Stephen J. Noga, Larry Dollar, Christopher A. Yasenchak, Peter Kelly, Sudhir Manda, Presley Whidden, Roger M. Lyons, Bingxia Wang, Ruemu Ejedafeta Birhiray, Robert M. Rifkin, Eric Chojnicki, Brittany Demers, Habte A. Yimer
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 19:e11
Autor:
Jesus G. Berdeja, Vania Hungria, Kaili Ren, Ajai Chari, Gordon Cook, Robert M. Rifkin, Jorge Vela-Ojeda, Roman Hájek, Hans C. Lee, Rafat Abonour, Tomas Skacel, Dawn Marie Stull, Caitlin Costello, Michael A. Thompson, Xavier Leleu, Katja Weisel, Brittany Demers, Andrew Spencer, Faith E. Davies, Saad Z. Usmani, Mario Boccadoro, Dorothy Romanus, Jeffrey A. Zonder, Evangelos Terpos, Noemi Puig, Jim Omel
Publikováno v:
Blood. 132:3289-3289
Background The introduction of multiple novel agents and regimens for NDMM and relapsed/refractory MM (RRMM) has improved outcomes while increasing the complexity of treatment selection and disease management. The real-world effectiveness of many nov